17.83 USD
+0.09 (+0.51%)
Taking everything into account, AVTX scores 4 out of 10 in our fundamental rating. AVTX was compared to 535 industry peers in the Biotechnology industry. While AVTX has a great health rating, there are worries on its profitability. AVTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AVTX had negative earnings in the past year.
AVTX had a negative operating cash flow in the past year.
AVTX had negative earnings in each of the past 5 years.
AVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AVTX's Return On Assets of -28.08% is fine compared to the rest of the industry. AVTX outperforms 69.04% of its industry peers.
Looking at the Return On Equity, with a value of -38.37%, AVTX is in the better half of the industry, outperforming 72.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -38.37% | ||
| ROIC | N/A |
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AVTX (182.99%) is better than 99.44% of its industry peers.
AVTX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 182.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
2. Health
2.1 Basic Checks
AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVTX has been increased compared to 1 year ago.
AVTX has more shares outstanding than it did 5 years ago.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.73, we must say that AVTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.73, AVTX is in line with its industry, outperforming 59.10% of the companies in the same industry.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.73 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
A Current Ratio of 14.28 indicates that AVTX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.28, AVTX belongs to the best of the industry, outperforming 90.24% of the companies in the same industry.
AVTX has a Quick Ratio of 14.28. This indicates that AVTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AVTX (14.28) is better than 90.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.28 | ||
| Quick Ratio | 14.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 95.12% over the past year.
The Revenue for AVTX has decreased by -77.08% in the past year. This is quite bad
AVTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.05% yearly.
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, AVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.63% on average per year.
Based on estimates for the next years, AVTX will show a very strong growth in Revenue. The Revenue will grow by 111.61% on average per year.
EPS Next Y96.35%
EPS Next 2Y40.19%
EPS Next 3Y25.54%
EPS Next 5Y14.63%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as AVTX's earnings are expected to grow with 25.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.19%
EPS Next 3Y25.54%
5. Dividend
5.1 Amount
AVTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AVTX (11/21/2025, 8:12:58 PM)
17.83
+0.09 (+0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.69%
Inst Owner Change97.37%
Ins Owners4.82%
Ins Owner Change0%
Market Cap234.46M
Revenue(TTM)441.00K
Net Income(TTM)-35.13M
Analysts86.67
Price Target34.39 (92.88%)
Short Float %11.85%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.71%
Min EPS beat(2)-33.98%
Max EPS beat(2)-29.44%
EPS beat(4)1
Avg EPS beat(4)-485.44%
Min EPS beat(4)-1889.97%
Max EPS beat(4)11.62%
EPS beat(8)1
Avg EPS beat(8)-1992.39%
EPS beat(12)4
Avg EPS beat(12)-1320.52%
EPS beat(16)7
Avg EPS beat(16)-983.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.42%
PT rev (3m)9.26%
EPS NQ rev (1m)13.2%
EPS NQ rev (3m)8.48%
EPS NY rev (1m)0%
EPS NY rev (3m)8.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 531.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.56 | ||
| P/tB | 2.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-13.31
EYN/A
EPS(NY)-5.69
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.97
OCFYN/A
SpS0.03
BVpS6.96
TBVpS6.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -38.37% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 182.99% | ||
| FCFM | N/A |
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.28 | ||
| Quick Ratio | 14.28 | ||
| Altman-Z | -0.73 |
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
EPS Next Y96.35%
EPS Next 2Y40.19%
EPS Next 3Y25.54%
EPS Next 5Y14.63%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
EBIT growth 1Y-74.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.07%
OCF growth 3YN/A
OCF growth 5YN/A
AVALO THERAPEUTICS INC / AVTX FAQ
Can you provide the ChartMill fundamental rating for AVALO THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to AVTX.
Can you provide the valuation status for AVALO THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to AVALO THERAPEUTICS INC (AVTX). This can be considered as Overvalued.
How profitable is AVALO THERAPEUTICS INC (AVTX) stock?
AVALO THERAPEUTICS INC (AVTX) has a profitability rating of 2 / 10.
What is the earnings growth outlook for AVALO THERAPEUTICS INC?
The Earnings per Share (EPS) of AVALO THERAPEUTICS INC (AVTX) is expected to grow by 96.35% in the next year.